Drug screening system for promoting microglial cells to transform to M2 phenotype as well as construction method and application of drug screening system

By constructing luciferase screening cell lines, using the chemiluminescence intensity of luciferase to screen small molecule drugs, the transformation of microglia to M2 phenotype is achieved, and the problem of regulating the M2 phenotype of microglia in the prior art is solved. , screen out potential small molecule drugs for the treatment of Alzheimer's disease.

CN118910212APending Publication Date: 2024-11-08BEIJING LIFE SCIENCE ACADEMY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411014513.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing drugs for Alzheimer's disease cannot reverse or prevent the progression of the disease, and there is a lack of efficient drug screening methods to regulate the transformation of microglia into the M2 phenotype, affecting the treatment of neurodegenerative diseases.

Method used

By constructing reporter genes containing the promoter of the spleen tyrosine kinase (Syk) gene and luciferase gene, cells were transfected with lentiviral plasmids, and luciferase screening cell lines were constructed. They could be activated by screening the chemiluminescence intensity of luciferase Small molecule drugs realize the transformation of microglia into M2 phenotype.

Benefits of technology

285 small molecules were successfully screened to activate the Syk gene. Tropisetron and LY2886721, two small molecules, have entered the Phase 3 clinical trial of Alzheimer's disease, providing a new treatment plan for neurodegenerative diseases such as Alzheimer's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910212A_ABST
    Figure CN118910212A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and particularly relates to a drug screening system for promoting microglial cells to transform to M2 phenotype as well as a construction method and application of the drug screening system. A chronic virus plasmid is constructed, the chronic virus plasmid comprises an EBFP2 gene, a Syk promoter and a downstream NanoLuc luciferase gene, the Syk promoter and the downstream NanoLuc luciferase gene are used for screening M2 phenotype microglial cells, then BV2 cells are transfected, and a luciferase screening cell line BV2-Syk-Nluc is obtained. According to the screening cell line, microglial cell M2 phenotype activation micromolecules are screened through chemiluminescence detection, the micromolecules with the chemiluminescence intensity higher than 1.5 are activation micromolecules, and the micromolecules with the chemiluminescence intensity lower than 0.5 are inhibition micromolecules. The screening cell line provided by the invention is an effective tool for screening Alzheimer's disease drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to a drug screening system for promoting the transformation of microglia to M2 phenotype, and a construction method and application thereof. Background Art

[0002] Alzheimer's disease (AD) is a degenerative disease of the central nervous system that mainly occurs in the elderly or pre-elderly. The main characteristics of the disease include progressive cognitive dysfunction and behavioral impairment. AD is the most common form of dementia. The pathogenesis of AD is still unclear. There are only four therapeutic drugs on the market (donepezil, galantamine, rivastigmine and memantine), all of which are mainly used to improve the clinical symptoms of AD. There is no effective drug that can reverse or prevent the progression of the disease.

[0003] Microglia are a type of mononuclear macrophage resident in the central nervous system. They are widely distributed throughout the brain and spinal cord. Their normal number and function are very important for maintaining the homeostasis of the nervous system. Microglia-mediated neuroinflammation is a common feature of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. In 2023, Professor Reisa Sperling of the Alzheimer's Disease Research and Treatment Center of Harvard Medical School published a prospective article in the journal Cell, pointing out that inducing microglia to transform into M2 phenotype is a potential treatment strategy for Alzheimer's disease. However, due to the lack of efficient drug screening methods, there are currently no drugs that regulate the M2 phenotype of microglia. Therefore, there is an urgent need to develop new high-throughput screening methods for small molecule drugs that activate M2 phenotype microglia to provide new tools for the development of therapeutic drugs for neurodegenerative diseases.

[0004] The reporter gene method uses the expression of reporter genes to evaluate the effects of drugs on signal pathways or genes, thereby understanding drug activity and analyzing drug action mechanisms. It is one of the common methods for biological activity detection and gene expression detection. Reporter genes are generally fluorescent proteins and luciferases, which have the advantage of being easy to detect and can be distinguished from endogenous proteins.

[0005] With the help of reporter genes, a reporter gene screening cell model can be constructed. In the target cells, the promoter of a specific target gene can be genetically modified to control the expression of the reporter gene. When the drug molecule can activate the expression of the promoter, a simple detection of the reporter gene expression can reveal the expression of the target gene and its downstream related pathways in the cell. This is a simple method for screening drugs that regulate cell phenotypes. Summary of the invention

[0007] In order to solve the above problems, the present invention provides a method for constructing a reporter gene through the spleen tyrosine kinase (Spleentyrosine83kinase, Syk) gene promoter (sequence as shown in SEQ ID NO.1), and then constructing a screening cell line, which is an efficient and highly sensitive microglial M2 phenotype regulation drug screening method. On the one hand, the present invention provides a drug screening method that promotes cell transformation to M2 phenotype, comprising the following steps:

[0008] S1. Construction of a lentiviral plasmid, wherein the lentiviral plasmid comprises a luciferase gene, a blue fluorescent protein gene and a promoter Syk, and the sequence of the Syk is shown in SEQ ID NO.1;

[0009] S2, transfecting cells with the lentiviral plasmid constructed in step S1 to obtain a screening cell line;

[0010] S3. Drug screening: The test substance is co-cultured with the screening cell line, and the chemiluminescence intensity of luciferase is used to screen small molecules that can activate M2 phenotype cells.

[0011] Specifically, the luciferase gene in step S1 includes, but is not limited to, firefly luciferase gene, Renilla 93 luciferase gene, Gaussia luciferase gene or Cyprinus luciferase gene.

[0012] More specifically, the luciferase gene in step S1 may be a firefly luciferase gene.

[0013] Preferably, the firefly luciferase gene may be a NanoLuc luciferase gene.

[0014] Further preferably, the NanoLuc luciferase gene sequence is shown as SEQ ID NO.2.

[0015] Specifically, the blue fluorescent protein gene in step S1 includes but is not limited to: EBFP, TagBFP / mTagBFP, Azurite or EBFP2.

[0016] More specifically, the blue fluorescent protein gene in step S1 may be EBFP2.

[0017] Preferably, the EBFP2 sequence is as shown in SEQ ID NO.3.

[0018] Specifically, the sequence of the lentiviral plasmid in step S1 is shown in SEQ ID NO.4.

[0019] Specifically, the cells in step S2 also include a helper plasmid.

[0020] More specifically, the auxiliary plasmid includes but is not limited to: one or more of pCMV-VSV-G, pMD2.G, 104pSPAX2 or pMDLg / pRRE.

[0021] Preferably, the helper plasmids may be pMD2.G and pSPAX2.

[0022] Specifically, the cells in step S2 are primary cells, immortalized cells or stem cells.

[0023] More specifically, the primary cells are cells that are extracted from an organism by a specific method and cultured directly;

[0024] The immortalized cells are obtained spontaneously or by transfection of exogenous genes, and can proliferate indefinitely and be passaged for a long time; the stem cells are a type of multidirectional differentiation potential cells with self-renewal and self-replication.

[0025] More specifically, the cells are immortalized cells.

[0026] Preferably, the immortalized cells are microglial cells.

[0027] Specifically, in step S3, the small molecule whose chemiluminescence intensity of luciferase is higher than 1.5 is an activating small molecule, and the small molecule whose chemiluminescence intensity of luciferase is lower than 0.5 is an inhibiting small molecule.

[0028] Specifically, the medicine also includes pharmaceutically acceptable excipients.

[0029] More specifically, the pharmaceutically acceptable excipient is selected from one or a combination of two or more of wetting agents, emulsifiers, preservatives, antioxidants, buffers, excipients, diluents, lubricants, antibacterial agents, suspending agents, suspending aids, solubilizers, thickeners, stabilizers, sweeteners and flavors.

[0030] Preferably, the pharmaceutically acceptable excipient is at least one selected from lactose, mannose, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, magnesium stearate and mineral oil. Specifically, the dosage form of the drug is tablets, liquids, capsules, powders, suppositories and granules. Specifically, the administration method of the drug is selected from oral administration, intravenous administration, topical administration, intradermal administration and / or subcutaneous administration.

[0031] In yet another aspect, the present invention provides a drug screening system, which is constructed by the aforementioned drug screening method.

[0032] In yet another aspect, the present invention provides use of the aforementioned drug screening system in screening drugs that promote the transformation of microglia to the M2 phenotype.

[0033] Specifically, the medicine also includes pharmaceutically acceptable excipients.

[0034] More specifically, the pharmaceutically acceptable excipient is selected from one or a combination of two or more of wetting agents, emulsifiers, preservatives, antioxidants, buffers, excipients, diluents, lubricants, antibacterial agents, suspending agents, suspending aids, solubilizers, thickeners, stabilizers, sweeteners and flavors.

[0035] Preferably, the pharmaceutically acceptable excipient is at least one selected from lactose, mannose, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, magnesium stearate and mineral oil. Specifically, the dosage form of the drug is tablets, liquids, capsules, powders, suppositories and granules. Specifically, the administration method of the drug is selected from oral administration, intravenous administration, topical administration, intradermal administration and / or subcutaneous administration.

[0036] In yet another aspect, the present invention provides a drug for promoting the transformation of microglia to an M2 phenotype, wherein the drug is obtained by the aforementioned drug screening method.

[0037] Specifically, the medicine also includes pharmaceutically acceptable excipients.

[0038] More specifically, the pharmaceutically acceptable excipient is selected from one or a combination of two or more of wetting agents, emulsifiers, preservatives, antioxidants, buffers, excipients, diluents, lubricants, antibacterial agents, suspending agents, suspending aids, solubilizers, thickeners, stabilizers, sweeteners and flavors.

[0039] Preferably, the pharmaceutically acceptable excipient is at least one selected from lactose, mannose, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, magnesium stearate and mineral oil. Specifically, the dosage form of the drug is tablets, liquids, capsules, powders, suppositories and granules. Specifically, the administration method of the drug is selected from oral administration, intravenous administration, topical administration, intradermal administration and / or subcutaneous administration.

[0040] The technical effects achieved by the present invention are as follows: 5706 small molecules were screened in high throughput through the constructed luciferase screening cell line BV2-Syk-Nluc, and small molecules activating the microglia M2 phenotype were screened through chemiluminescence detection. A total of 285 small molecules were found to be able to activate the Syk gene by more than 1.5, and two of them, Tropisetron and LY2886721, have entered the Phase 3 clinical trial of Alzheimer's disease, indicating that they are potential small molecule drugs for activating the microglia M2 phenotype. Small molecules can be selected from them for subsequent research to provide new treatment options for neurodegenerative diseases such as Alzheimer's disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 Figure 1 is a map of the lentiviral plasmid containing the reporter gene of the embodiment.

[0043] Figure 2 Schematic diagram of the high-throughput screening experiment process.

[0044] Figure 3 Schematic diagram of cell line construction for luciferase screening.

[0045] Figure 4 Schematic diagram of the luciferase reaction.

[0046] Figure 5 This is the result of flow cytometry sorting of luciferase screening cell lines, where the cell population on the left is non-BFP response cells, and the cell population on the right is BFP response cells, that is, the cells need to be collected.

[0047] Figure 6 This is a graph of the positive verification results of agarose gel. The BV2-Syk-Nluc luciferase screening cell line has a BFP gene sequence response, while the control group BV2 result is negative.

[0048] Figure 7 The results of the reverse transcription quantitative PCR experiment are shown, showing the RNA expression of different phenotypic marker genes in negative control, BV2 cells treated with Dex for 24 hours, and BV2 cells treated with LPS for 24 hours; (a) is the result of the reverse transcription quantitative PCR experiment of the microglial M2 phenotype gene; (b) is the result of the reverse transcription quantitative PCR experiment of the microglial M1 phenotype gene; a two-way ANOVA (95% confidence level) was used for significance testing. **** indicates p<0.0001, *** indicates p<0.001, ** indicates p<0.01, and * indicates p<0.05; ns indicates that the result is not significant.

[0049] Figure 8The results of protein immunoblotting experiments, negative control, Dex-treated BV2-Syk-Nluc for 24 hours, and Dex-treated BV2-Syk-Nluc for 48 hours; (a) is the result of protein immunoblotting; (b) is the quantitative analysis of protein immunoblotting results; grayscale quantitative analysis of protein immunoblotting bands was performed, with housekeeping gene Actb as the internal reference, and 2 -ΔCt The target gene mRNA expression levels were calculated, and the relevant expression results of Arg1 in the control group and the experimental group were obtained.

[0050] Fig. 9 The graph shows the results of chemiluminescence detection, including negative control, BV2-Syk-Nluc treated with Dex for 24 hours, and BV2-Syk-Nluc treated with LPS for 24 hours.

[0051] Fig.10 For small molecules that activate the M2 phenotype of microglia, the relative chemiluminescence intensity of small molecules in the six compound libraries is displayed. When the ratio of the chemiluminescence intensity of the untreated control group is ≥1.5, it is an activated small molecule.

[0052] Fig.11 The analysis of the cellular pathways activated by small molecules for the M2 phenotype of microglia showed the classification of the cellular action pathways of 285 activated small molecules and the number of small molecules that can play a regulatory role in the pathway.

[0053] Fig.12 It is the chemiluminescent signal ratio of marker gene promoters Syk, Arg1, Fizz1, Klf4, Srf, and Ym1. DETAILED DESCRIPTION

[0054] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0055] Example 1

[0056] 1.1 Construction of stably transfected cell lines

[0057] The lentiviral plasmid constructed in the present invention is G0285809-1 (pYY006-mSyk) with a map as shown in Figure 1As shown, the sequence is shown in SEQ ID NO.4, including the EBFP2 gene for screening successfully transfected cells (the sequence is shown in SEQ ID NO.3), and the Syk promoter (the sequence is shown in SEQ ID NO.1) and the downstream NanoLuc luciferase gene (the sequence is shown in SEQ ID NO.2) for screening M2 phenotype microglia.

[0058] 293FT cells and BV2 cells were obtained from the National Laboratory Cell Line Resource Sharing Platform. 293FT cells were cultured in DMEM medium containing 10% FBS, 1% penicillin / streptomycin, NEAA, and GlutaMAX at 37°C / 5% CO2. BV2 cells were cultured in MEM medium containing 10% FBS, 1% MEM non-essential amino acids, and 1% penicillin / streptomycin (MEM complete medium) at 37°C / 5% CO2.

[0059] Stably transfected cell lines were obtained by drug screening after stable transfection with lentivirus. First, 293FT cells were cultured in a six-well cell culture plate. When they grew to 80%-90% density, the ordinary culture medium was replaced with Ultra-MEM reduced serum medium containing 5% FBS for 2 hours. Take 250μL Ultra-MEM reduced serum medium, add 0.5μg G0285809-1 (pYY006-mSyk), 0.5μg pMD2.G plasmid (Addgene#12259), and 0.5μg pSPAX2 plasmid (Addgene#12260) to make solution A. Take another 250μL Ultra-MEM reduced serum medium and add 3μL Liposome transfection reagent was used to prepare solution B. Equal volumes of solution A and solution B were mixed and incubated at room temperature for 20 minutes. The mixture was then added to the culture medium of 293FT cells to produce lentivirus.

[0060] 24 hours and 72 hours after transfection, the reduced serum medium of 293FT cells was aspirated, centrifuged at 2,000 rpm for 10 minutes, and then filtered through a 0.45 μm filter membrane to obtain the lentiviral solution. The obtained lentiviral solution was divided and stored in a -80°C refrigerator.

[0061] The BV2 cells to be transfected were cultured in a six-well cell culture plate. When the density was 70%-80%, the normal culture medium was replaced with the lentiviral transfection medium. The lentiviral medium consisted of 200 μL lentiviral solution, 1800 μL normal culture medium and 0.8 μL polybrene. Subsequent experiments were performed 48 hours after lentiviral transfection.

[0062] SEQ ID NO.1:

[0063]

[0064] SEQ ID NO.2:

[0065] ATGGTCTTCACACTCGAAGATTTCGTTGGGGACTGGCGACAGACAGCCGGCTACAACCTGGACCAAGTCCTTGAACAGGGAGGTGTGTCCAGTTTGTTTCAGAATCTCGGGGTGTCCGTAACTCCGATCCAAAGGATTGTCCTGAGCGGTGAAAATGGGCTGAAGATCGACATCCATGTCATCATCCCGTATGAAGGTCTGAGCGGCGACCAAATGGGCCAGATCGAAAAAATTTTTAAGGTGGTGTACCCTGTGGATGATCATCACTTTAAGGTGATCCTGCACTATGGCACACTGGTAATCGACGGGGTTACGCCGAACATGATCGACTATTTCGGACGGCCGTATGAAGGCATCGCCGTGTTCGACGGCAAAAAGATCACTGTAACAGGGACCCTGTGGAACGGCAACAAAATTATCGACGAGCGCCTGATCAACCCCGACGGCTCCCTGCTGTTCCGAGTAACCATCAACGGAGTGACCGGCTGGCGGCTGTGCGAACGCATTCTGGCGTAG;

[0066] SEQ ID NO.3:

[0067] atggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgaggggcgagggcgagggcgatgccaccaacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgagccacggcgtgcagtgcttcgcccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcacctacaagacccgcgccgaggtgaagttcgagggcgacaccctagtgaaccgcatcgagctgaagggcgtcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaacttcaacagccacaacatctatatcatggccgtcaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacgtggaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacagccactacctgagcacccagtccgtgctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttccgcaccgccgccgggatcactctcggcatggacgagctgtacaagtaa;

[0068] SEQ ID NO.4:

[0069]

[0070] 1.2 Flow cytometry sorting experiment

[0071] For BV2 cells that had been transfected with lentivirus for 48 hours, the cell culture fluid was collected, and the adherent cells were washed with PBS heated at 37°C, and then 1×Trypsin was added for digestion for 3 minutes. Trypsin was added to an equal volume of normal culture medium to terminate the digestion and collect. The collected cell culture fluid and cell suspension were centrifuged at 2,000rpm for 3 minutes. The supernatant was removed, resuspended in 200μL PBS, centrifuged at 2,000rpm for 3 minutes, and resuspended in 300μL normal culture medium. The resuspended solution was transferred to a flow tube, and the positive cell population of the 405nm excitation channel was sorted out by a flow analyzer. A 24-well cell culture plate was used to receive positive cells, namely the BV2-Syk-Nluc screening cell line, and cultured in normal culture medium for subsequent experiments.

[0072] 1.3 Nucleic acid gel electrophoresis experiment

[0073] use The genomic DNA of BV2-Syk-Nluc screening cell line and BV2 cells was extracted using a blood / cell / tissue genomic DNA extraction kit. PCR was performed using blue fluorescent protein gene primers (Table 1). The procedure is shown in Table 2.

[0074] Table 1

[0075] name Sequence (5'-3') SEQ ID NO. DNA Primer-F GCTGGACGGCGACGTAAAC SEQ ID NO.5 DNA Primer-R GTTGCGTCAGCAAACACAGT SEQ ID NO.6

[0076] Table 2

[0077]

[0078] Prepare 1% agarose gel, perform electrophoresis at 120V for 45 minutes, take pictures and save them.

[0079] 1.4 Reverse transcription quantitative PCR experiment

[0080] Three BV2-Syk-Nluc cells were cultured in a six-well cell culture plate. When the cell density was 20%-30%, the medium was changed to normal culture medium, normal culture medium containing 2nM dexamethasone, and normal culture medium containing 200ng / mL LPS. After 24 hours of culture, Biozol total RNA extraction reagent (Bai Ruiji, catalog number: BN20537-100ml) was used to extract total cell RNA according to the instructions. The RNA concentration was determined using a Nanodrop 2000UV-vis spectrophotometer.

[0081] according to The extracted RNA was reverse transcribed using the First Strand cDNA Synthesis Kit (Yisheng, Cat. No.: 11119ES60) instructions. Advanced qPCR SYBR Master Mix (Yisheng, catalog number: 11185ES03) was used to perform qPCR experiments on cDNA. The primers are shown in Table 3. The real-time fluorescence of the samples was detected by Bio-Rad CFX96 real-time fluorescence detector, and the Ct value was calculated. The average value was taken after removing the maximum value of the four repeated experiments, and the housekeeping gene Actb was used as the internal reference. -ΔΔCt Calculate the target gene mRNA expression level.

[0082] Table 3

[0083]

[0084]

[0085] 1.5 Western blotting

[0086] Three BV2-Syk-Nluc cells were cultured in a six-well cell culture plate. When the cell density reached 20%-30%, the medium was changed to normal culture medium, normal culture medium containing 2 nM dexamethasone, and normal culture medium containing 200 ng / mL LPS.

[0087] After 24 hours of culture, cells were lysed and whole proteins were extracted according to the instructions of Western Blotting and Immunoprecipitation (WB / IP) lysis buffer. The whole protein concentration of cells was determined by BCA protein concentration determination kit. Whole cell proteins were separated using 4%-20% SDS-PAGE precast gel and then transferred to nitrocellulose (NC) membrane.

[0088] Prepare 1×TBST solution to wash the NC membrane three times, block the free binding sites with 5% skim milk powder, and then incubate with the primary antibody at room temperature for 1 hour. Wash three times with 1×TBST solution, and then incubate with HRP-labeled secondary antibody at room temperature for 1 hour. Wash three times with 1×TBST solution, mix equal volumes of ELC chemiluminescent kit A solution and B solution and drop them onto the NC membrane, and use Gel Dox XR+ gel recording system to detect the chemiluminescent signal of the NC membrane. The formula of primary and secondary antibodies is shown in Table 4.

[0089] Table 4

[0090]

[0091] 1.6 Luciferase chemiluminescence detection experiment

[0092] Three BV2-Syk-Nluc cells were cultured in a six-well cell culture plate. When the cell density was 20%-30%, the medium was changed to normal culture medium, normal culture medium containing 2nM dexamethasone, and normal culture medium containing 200ng / mL LPS. After 24 hours of culture, the whole cell protein was extracted by digestion using Lysis Buffer. The luciferase reaction substrate Furi solution was prepared, and the formula is shown in Table 5. Take 10μL of whole protein in a full white 384-well cell culture plate, add 10μL of Furi solution, and quickly use the Cytation C10 confocal microplate imaging detector to detect the chemiluminescence intensity.

[0093] Table 5

[0094]

[0095] 1.7 High-throughput screening experiments

[0096] Use 96-well cell culture plates to pick up small molecules from six compound libraries of the drug screening platform of Tsinghua University, each at 100μL / 10mM or 500μL / 2mM. BV2-Syk-Nluc cells were laid in 96-well cell culture plates. After the cells adhered (about 24 hours), the small molecules were dissolved in ordinary culture medium, and the cells were replaced with drug solutions. Each 96-well plate has a column of untreated cells as a control group.

[0097] After 24 hours of incubation with drugs, the supernatant was aspirated, washed with PBS, and lysed with Lysis Buffer to obtain the total protein of the cells. The lysate was transferred to a white 96-well plate, and the same volume of Furi solution was added, and its chemiluminescence intensity was quickly detected.

[0098] The average chemiluminescence intensity of the control group cells without drug addition in each plate was calculated, and the chemiluminescence value of the cells after drug incubation was divided by the average value. The small molecules with a result higher than 1.5 are activating small molecules, while those with a result lower than 0.5 are inhibiting small molecules.

[0099] Figure 2 The high-throughput screening experimental process is demonstrated. First, cells are cultured in a 96-well plate, and then drugs are added and cultured for 24 hours before measuring the luciferase chemiluminescence intensity.

[0100] 1.8 Experimental results and analysis

[0101] 547 First, a plasmid for luciferase screening cell lines was designed. To construct a suitable screening cell line, the 548 Syk gene promoter was used as the promoter of the luciferase NanoLuc reporter gene. When microglia transform to the M2549 phenotype, the Syk gene will be activated. In other words, the activity of the Syk gene promoter is enhanced, and the expression of the luciferase encoded by the plasmid 550 increases. Figure 4 The luminescence principle of NanoLuc is demonstrated. NanoLuc uses Furimazine551 (a new type of coelenterazine) as a reaction substrate and does not rely on ATP. It emits light signals through redox reactions. 552 When the reaction substrate Furimazine (a new type of coelenterazine) is sufficient, the NanoLuc content increases, and the light signal will increase accordingly, so it can easily and quickly reflect the genetic changes in microglia. In the plasmid, a blue fluorescent protein reporter gene sequence guided by a non-Syk gene promoter is also designed. When the plasmid is introduced into the cell555, the blue fluorescent protein is expressed, which reflects the introduction of the plasmid.

[0102] 556 Then, the plasmid was synthesized by Gibson Assembly, and a stable screening 557 cell line was constructed by lentiviral transfection. Lentivirus transfection uses retrovirus as a vector and integrates exogenous genes into the gene 558 group through reverse transcriptase, so that the host cells can express the exogenous genes stably for a long time, thereby obtaining a more stable screening cell 559 line. BV2 is an immortalized mouse microglia cell, which has the phenotype, morphology 560 and various unique functions of primary microglia, and is more stable and easier to culture than primary microglia. 561 After lentiviral transfection, the luciferase gene, the blue fluorescent protein gene and its promoter will be integrated into the 562 BV2 cell genome and stably expressed under the activation of transcription factors. Using blue fluorescent protein as a reporter gene, 563 the transfected cells were sorted by flow cytometry. The luciferase screening cell line was named BV2-Syk-Nluc, 564 as Figure 5 As shown, after transfection, cells will be divided into groups compared to BV2 cells, and the newly emerged cell groups have a blue fluorescence response, indicating that the plasmid has been successfully introduced into the cells. The responding cell groups were collected and cultured to obtain the BV2-Syk-Nluc luciferase screening cell line.

[0103] To further verify the results of cell line construction, primers were designed based on the coding near the blue fluorescent protein, and 568 cell DNA was extracted for PCR. The product length was 1000 bp. The corresponding band would only appear when the plasmid was successfully transferred into the cell. Figure 6 As shown, the results of BV2 cells were negative, and the results of BV2-Syk-Nluc cells were positive, confirming the successful construction of the luciferase screening cell line.

[0104] 571 Before high-throughput screening, the function of the constructed BV2-Syk-Nluc screening cell line needs to be verified. 572 First, it is necessary to verify that the BV2-Syk-Nluc cell line can be activated by drugs and polarized to the M1 / M2 phenotype. 573 Studies have shown that dexamethasone (Dex) can reduce tissue responses to inflammation, inhibit cell-mediated immune responses, and promote the transformation of microglia from the M1 phenotype to the M2 phenotype. Bacterial 575 endotoxin (lipopolysaccharide, LPS) is the most commonly used microglial proinflammatory stimulant in vitro and in vivo, which can promote 576 microglia to polarize to the M1 phenotype. The BV2-Syk-Nluc577 cell line was treated with dexamethasone and lipopolysaccharide for 24 hours, and the cell state was further verified by reverse transcription quantitative PCR experiments. Microglial 578M1 phenotype polarization markers include CD11b, CD16, CD32, CD80 and CD86, while microglial 579M2 phenotype polarization markers include CD206, Arg1, Fizz-1, CD68, CCL-22, Ym1 / 2, IL-10580, etc. Figure 7 As shown, the BV2-Syk-Nluc cell line was subjected to 582 reverse transcription quantitative PCR experiments for 4 M2 phenotype polarization marker gene RNAs and 2 M1 phenotype polarization marker gene RNAs after 24 hours of dexamethasone and lipopolysaccharide treatment. Comparison of the experimental group results showed that microglia treated with dexamethasone were more 583 biased towards M2 phenotype polarization, while microglia treated with lipopolysaccharide were more 584 biased towards M1 phenotype polarization, which was consistent with the expected polarization results of microglia 585 cells after drug treatment. Therefore, the insertion of the designed reporter gene DNA sequence will not 586 affect the cell's response to the drug, and the BV2-Syk-Nluc cell line is in a normal state and can be used for subsequent experiments. 587 Arg1 is one of the most important markers of microglial M2 phenotype polarization, so the BV2-Syk-Nluc588 cell line and its drug-treated cells were subjected to Arg1 protein immunoblotting experiments for further 588 verification at the protein level. The molecular weight of Arg1 protein is 35kDa, while that of Actb protein is 42kDa. The results of protein 589 immunoblotting experiments were quantitatively analyzed. Negative control (Ctrl), Dex-treated BV2-Syk-Nluc 24590 hours (Dex-24h), Dex-treated BV2-Syk-Nluc 48 hours (Dex-48h). Grayscale quantitative analysis of protein immunoblot 591 bands was performed, with housekeeping gene Actb as internal reference. By 2 -ΔCt The expression level of target gene 592 mRNA was calculated, and the relevant expression results of Arg1 in the control group and experimental group were obtained.

[0105] 593 Results Schematic Diagram Figure 8As shown, (a) Western blot results; (b) Western blot results quantitative analysis. Under the action of Dex, the expression of Arg1, a marker of the M2 phenotype of microglia, increased in the BV2-Syk-Nluc screening cell line, further confirming that the constructed screening cell line can normally reflect the polarization of microglia under the action of drugs.

[0106] 597Then we need to verify the ability of BV2-Syk-Nluc to screen cell lines with luciferase expression levels that change with M1 / M2 phenotype polarization, and then confirm that it can react to the microglia activation ability of drugs through chemiluminescence. The whole cell protein was extracted for chemiluminescence detection, and the results were as follows Fig. 9 The chemiluminescence intensity of cells treated with dexamethasone was slightly higher than that of the control group, while that of cells treated with lipopolysaccharide was lower than that of the control group, which proved that the BV2-Syk-Nluc cell line could reflect the cell polarization state through the chemiluminescence results of luciferase, and was further used to screen small molecules that could activate M2 phenotype microglia.

[0107] High-throughput screening was performed by chemiluminescence detection experiments. The chemiluminescence intensity of BV2-Syk-Nluc cells treated with small molecules in the compound library for 24 hours was compared with the results without drug treatment. Small molecules with a value higher than 1.5 activated the M2 phenotype of microglia, and small molecules with a value lower than 0.5 inhibited the M2 phenotype of microglia. Fig.10 As shown, a total of 285 small molecules were found to be able to activate the Syk gene by more than 1.5, and two of them, Tropisetron and LY2886721, have entered the Phase 3 clinical trial for Alzheimer's disease, indicating that they are potential small molecule drugs for activating the M2 phenotype of microglia. Small molecules can be selected from them for subsequent research to provide new treatment options for neurodegenerative diseases such as Alzheimer's disease.

[0108] The cell regulation pathways of small molecules activated by microglia M2 phenotype were statistically analyzed, and the results are as follows: Fig.11 As shown, one-third of small molecules can regulate cell metabolism, many small molecules have anti-infection effects, and some molecules play a role in the cell signaling pathways of inflammation and neural signal transduction, which may promote the anti-inflammatory and neuroprotective effects of microglia and are potential drugs for the treatment of Alzheimer's disease.

[0109] Comparative Example

[0110] A reporter gene consisting of the promoter of a typical M2 phenotype microglial marker gene was constructed, including genes such as Arg1, Fizz1, Klf4, Srf, and Ym1. Arg1, Fizz1, Klf4, Srf, and Ym1 were used to replace the Syk promoter sequence of this embodiment, and the sequences of the Arg1, Fizz1, Klf4, Srf, and Ym1 genes are shown in SEQ ID NO.21-SEQID NO.25, respectively. Referring to the method of the embodiment, a BV2 stable cell line expressing these reporter genes was constructed, and dexamethasone was added to induce the cells to an M2 phenotype, and then the chemiluminescent signal ratio of each group before and after the addition of the drug was detected by an enzyme marker. The results are shown in FIG. Fig.12 As shown, the signal-to-noise ratio of the Syk promoter provided by the present invention is significantly higher than that of other common M2 marker gene promoters, and is more suitable for drug screening.

[0111] SEQ ID NO.21:

[0112]

[0113] SEQ ID NO.22:

[0114]

[0115] SEQ ID NO.23:

[0116]

[0117] SEQ ID NO.24:

[0118]

[0119] SEQ ID NO.25:

[0120]

[0121] GAGTTGCCCATAACATCCTAAATGCCCTTAGATAATGATCTCAGAATTAAGG

[0122] TAACTGAATGAAGGCAGCAAAATGTCTTCCATGGAATCAACTTGTTTATTTT

[0123] TCTATGTGAATAAGATTTGTCTAGGTATAAAATATATACAATAAGCATTAATTC

[0124] TAATATCCAAAGATATGCTGAGTCCCTGGGAACTGCCAATATGGTCTTAGCT

[0125] GGATGATTGATACATAATGTAAAGAAATACCCACTTCTTAGAAACATAGCTA

[0126] TCTTGACTGAACTGGTGATAAAAGGTGCCGGGTTATCTATTAAGGGGGCTTA

[0127] TTCAGCAGTATGAAGCTATTAATTAAAAGATTATTCGCAAACACTTCCTTTT

[0128] CCAAACTTCCCATTTTCAAAACATTACAAAATCATGGTCTCGGAGTATATAA

[0129] AAAGCCAGCAGAAGCTCTCCAGAAGC。

Claims

1. A method for screening drugs that promote cell transformation to M2 phenotype, characterized in that: The following steps are involved: S1. Construction of a lentiviral plasmid, wherein the lentiviral plasmid comprises a luciferase gene, a blue fluorescent protein gene and a promoter Syk, and the sequence of the Syk is shown in SEQ ID NO.1; S2, transfecting cells with the lentiviral plasmid constructed in step S1 to obtain a screening cell line; S3. Drug screening: The test substance is co-cultured with the screening cell line, and the chemiluminescence intensity of luciferase is used to screen small molecules that can activate M2 phenotype cells.

2. The drug screening method according to claim 1, characterized in that The luciferase gene in step S1 is a firefly luciferase gene, a Renilla luciferase gene, a Gaussia luciferase gene or a Cypridina luciferase gene.

3. The drug screening method according to claim 2, characterized in that: The luciferase gene in step S1 is a firefly luciferase gene.

4. The drug screening method according to any one of claims 1 to 3, characterized in that: The firefly luciferase gene is a NanoLuc luciferase gene with a sequence as shown in SEQ ID NO.

2.

5. The drug screening method according to claim 1, characterized in that: In step S1, the blue fluorescent protein gene is EBFP, TagBFP / mTagBFP, Azurite or EBFP2.

6. The drug screening method according to claim 5, characterized in that: The blue fluorescent protein gene in step S1 is EBFP2 with a sequence as shown in SEQ ID NO.

3.

7. The drug screening method according to claim 1, characterized in that: The sequence of the lentiviral plasmid in step S1 is shown in SEQ ID NO.

4.

8. The drug screening method according to claim 1, characterized in that: The cells in step S2 also include a helper plasmid.

9. The drug screening method according to claim 8, characterized in that: The auxiliary plasmid is one or more of pCMV-VSV-G, pMD2.G, pSPAX2 or pMDLg / pRRE.

10. The drug screening method according to claim 8 or 9, characterized in that: The auxiliary plasmids are pMD2.G and pSPAX2.

11. The drug screening method according to claim 1, characterized in that: The cells in step S2 are primary cells, immortalized cells or stem cells.

12. The drug screening method according to claim 11, characterized in that: The cells are immortalized cells.

13. The drug screening method according to claim 11 or 12, characterized in that: The immortalized cells are microglial cells.

14. The drug screening method according to claim 1, characterized in that: In step S3, the small molecules whose chemiluminescence intensity of luciferase is higher than 1.5 are activating small molecules, and those whose chemiluminescence intensity is lower than 0.5 are inhibiting small molecules.

15. A drug screening system, characterized in that: The drug screening system is constructed by the drug screening method according to any one of claims 1 to 14.

16. Use of the drug screening system according to claim 15 in screening drugs that promote the transformation of microglia to M2 phenotype.

17. A drug for promoting the transformation of microglia to M2 phenotype, characterized in that: The drug is obtained by the drug screening method according to any one of claims 1 to 14.